SCHEMBL13499747

SCHEMBL13499747

CC(C)NC(=O)C(CC1CC1C)OCC1CCCC1

nearest known ligand 0.36

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
SLC1A3 P43003 4/20 0.36
SLC1A2 P43004 4/20 0.36
SLC1A1 P43005 4/20 0.36
CTSK P43235 4/20 0.33
CTSS P25774 1/20 0.33
LTA4H P09960 1/20 0.33
GPR88 Q9GZN0 3/20 0.32
CTSL P07711 2/20 0.30
CTSB P07858 2/20 0.30
METAP2 P50579 1/20 0.30
CTSH P09668 1/20 0.30
SMN1; SMN2 Q16637 1/20 0.30
PDE4A P27815 1/20 0.30
PDE4B Q07343 1/20 0.30
PDE4C Q08493 1/20 0.30
PDE4D Q08499 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13499739 0.96 PDE4A (0.33) SLC1A3SLC1A2SLC1A1CTSKCTSS
SCHEMBL13500285 0.87 SLC1A3 (0.37) SLC1A3SLC1A2SLC1A1CTSKCTSS
SCHEMBL13499742 0.87 SLC1A3 (0.41) SLC1A3SLC1A2SLC1A1CTSKCTSS
SCHEMBL13499735 0.85 SLC1A3 (0.40) SLC1A3SLC1A2SLC1A1CTSKCTSS
SCHEMBL13499746 0.85 SLC1A3 (0.40) SLC1A3SLC1A2SLC1A1CTSKCTSS
SCHEMBL13499743 0.85 SLC1A3 (0.40) SLC1A3SLC1A2SLC1A1CTSKCTSS
SCHEMBL13461408 0.85 SLC1A3 (0.35) SLC1A3SLC1A2SLC1A1CTSKCTSS
SCHEMBL13435116 0.84 CPB2 (0.35) SLC1A3SLC1A2SLC1A1CTSKCTSS
SCHEMBL13499711 0.83 MEN1 (0.33)
SCHEMBL13499731 0.82 MEN1 (0.31)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100048541-A1 SUBSTITUTED LACTAMS AS INHIBITORS OF ABETA PROTEIN PRODUCTION BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) 2010-02-25 US disclosed
US-7655647-B2 Substituted lactams as inhibitors of Aβ protein production BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) 2010-02-02 US disclosed
US-7655647-B2 Substituted lactams as inhibitors of Aβ protein production BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) 2010-02-02 US disclosed
US-20090170831-A1 SUBSTITUTED LACTAMS AS INHIBITORS OF ABETA PROTEIN PRODUCTION BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) 2009-07-02 US disclosed
US-20090170831-A1 SUBSTITUTED LACTAMS AS INHIBITORS OF ABETA PROTEIN PRODUCTION BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) 2009-07-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100048541-A1 SUBSTITUTED LACTAMS AS INHIBITORS OF ABETA PROTEIN PRODUCTION BACE1, APP, APH1A SLC1A3 801/4885SLC1A2 537/4885SLC1A1 743/4885
US-20090170831-A1 SUBSTITUTED LACTAMS AS INHIBITORS OF ABETA PROTEIN PRODUCTION BACE1, APP, APH1A SLC1A3 864/4885SLC1A2 667/4885SLC1A1 785/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.